Business
‘Another string in our bow’: Novavax prepares for COVID-19 vaccine launch – Sydney Morning Herald
Maryland-based Novavax has finalised its deal with the Australian government for 51 million doses of its vaccine.
The technology behind Novavax’s coronavirus vaccine is different from other products that Australia has ordered. The protein-based candidate contains one element of the virus, a version of the “spike protein” in SARS-CoV-2, and the vaccine delivers this to the body to prompt an immune response.
Unlike mRNA vaccines like Pfizer’s, which must be stored at very low temperatures,Novavax’s product is designed to be more easily stored with standard refrigeration methods.
Novavax’s vaccine is in phase…
Continue Reading
